4D Molecular Therapeutics (NASDAQ:FDMT) Insider David Kirn Sells 15,725 Shares

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) insider David Kirn sold 15,725 shares of the stock in a transaction on Friday, July 10th. The stock was sold at an average price of $12.03, for a total transaction of $189,171.75. Following the completion of the sale, the insider owned 884,152 shares in the company, valued at $10,636,348.56. The trade was a 1.75% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

David Kirn also recently made the following trade(s):

• On Thursday, July 9th, David Kirn sold 42,608 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $12.87, for a total transaction of $548,364.96.
• On Monday, June 22nd, David Kirn sold 114,746 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.47, for a total transaction of $1,201,390.62.
• On Monday, June 1st, David Kirn sold 1,922 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.02, for a total transaction of $19,258.44.

4D Molecular Therapeutics Stock Up 3.5%

4D Molecular Therapeutics stock opened at $11.70 on Wednesday. The business’s 50-day moving average price is $10.30 and its 200 day moving average price is $9.39. The firm has a market cap of $611.68 million, a price-to-earnings ratio of -4.55 and a beta of 2.70. 4D Molecular Therapeutics, Inc. has a 52 week low of $4.11 and a 52 week high of $14.00.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its earnings results on Thursday, May 7th. The company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of ($0.97) by ($0.04). 4D Molecular Therapeutics had a negative net margin of 182.34% and a negative return on equity of 36.83%. The firm had revenue of $3.05 million for the quarter, compared to analysts’ expectations of $2.59 million. Equities analysts expect that 4D Molecular Therapeutics, Inc. will post -4.14 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research firms have weighed in on FDMT. Chardan Capital reaffirmed a “buy” rating and issued a $26.00 price objective on shares of 4D Molecular Therapeutics in a report on Thursday, March 19th. Jefferies Financial Group restated a “buy” rating and set a $21.00 target price (down from $40.00) on shares of 4D Molecular Therapeutics in a research report on Monday, March 30th. HC Wainwright restated a “buy” rating and issued a $36.00 price target on shares of 4D Molecular Therapeutics in a research note on Friday, March 20th. The Goldman Sachs Group set a $33.00 price target on 4D Molecular Therapeutics in a report on Friday, May 8th. Finally, Royal Bank Of Canada increased their price target on 4D Molecular Therapeutics from $32.00 to $35.00 and gave the stock an “outperform” rating in a research report on Thursday, March 19th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $29.88.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Janus Henderson Group PLC lifted its stake in 4D Molecular Therapeutics by 164.4% in the 4th quarter. Janus Henderson Group PLC now owns 4,635,875 shares of the company’s stock valued at $34,726,000 after buying an additional 2,882,508 shares in the last quarter. State Street Corp increased its stake in 4D Molecular Therapeutics by 197.5% during the 4th quarter. State Street Corp now owns 2,688,880 shares of the company’s stock worth $20,167,000 after buying an additional 1,785,106 shares in the last quarter. RA Capital Management L.P. raised its holdings in shares of 4D Molecular Therapeutics by 23.9% during the fourth quarter. RA Capital Management L.P. now owns 5,653,211 shares of the company’s stock valued at $42,399,000 after acquiring an additional 1,090,000 shares during the last quarter. Adage Capital Partners GP L.L.C. raised its holdings in shares of 4D Molecular Therapeutics by 605.8% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 1,235,156 shares of the company’s stock valued at $9,264,000 after acquiring an additional 1,060,156 shares during the last quarter. Finally, Evergreen Quality Fund GP Ltd. purchased a new position in shares of 4D Molecular Therapeutics in the fourth quarter valued at approximately $7,136,000. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.